Undifferentiated carcinoma of the corpus uteri

Undifferentiated carcinoma of the corpus uteri is an extremely rare and aggressive malignant tumor arising from the body (corpus) of the uterus. Unlike the more common endometrial carcinomas, undifferentiated carcinoma lacks any specific histological differentiation — meaning the tumor cells do not resemble normal endometrial glandular, squamous, or other recognizable tissue patterns. This absence of differentiation is associated with highly aggressive biological behavior and a poor prognosis. The disease primarily affects the female reproductive system, specifically the uterine corpus, but can spread (metastasize) to regional lymph nodes, the peritoneum, lungs, liver, and other distant organs. Key symptoms may include abnormal uterine bleeding (particularly postmenopausal bleeding), pelvic pain, an enlarged uterus, and symptoms related to advanced or metastatic disease such as weight loss, fatigue, and abdominal distension. Diagnosis is established through histopathological examination of biopsy or surgical specimens, often requiring immunohistochemical studies to distinguish it from other poorly differentiated uterine malignancies such as dedifferentiated endometrial carcinoma, high-grade endometrial stromal sarcoma, or carcinosarcoma. Treatment typically involves surgical management with total hysterectomy and bilateral salpingo-oophorectomy, often accompanied by lymph node dissection and staging. Due to the aggressive nature of this tumor, adjuvant chemotherapy (often platinum-based regimens) and/or radiation therapy are frequently employed. Despite multimodal treatment, outcomes remain poor compared to more differentiated endometrial cancers, with high rates of recurrence. Research into targeted therapies and immunotherapy approaches is ongoing but no specific targeted treatments have been established for this entity.

Common questions about Undifferentiated carcinoma of the corpus uteri